British journal of clinical pharmacology · 2026
Neonatal PBPK model of midazolam and its metabolites for perinatal asphyxia and therapeutic hypothermia.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Leys Karen, Ozbey Agustos, Huang Miao-Chan, Macente Julia, Stroe Marina-Stefania, de Haan Timo Robert, Groenendaal Floris, Jacqz-Aigrain Evelyne, de Wildt Saskia N, Allegaert Karel, Van Cruchten Steven, Smits Anne, Annaert Pieter
Аннотация
BACKGROUND AND PURPOSE: Therapeutic hypothermia (TH) decreases morbidity and mortality in neonates with perinatal asphyxia (PA) and moderate-to-severe hypoxic-ischaemic encephalopathy. Midazolam is an antiepileptic and substrate of CYP3A4. Drug metabolism during PA/TH remains partially characterized, and disentangling effects of PA and TH is difficult, making precision dosing challenging. The I-PREDICT project aims to develop a framework for drug disposition in PA/TH neonates, using physiologically based pharmacokinetic (PBPK) modelling. The predictive performance of the model was explored for midazolam and its active metabolites, 1'-hydroxymidazolam and 1'-hydroxymidazolam-O-glucuronide, in neonates with PA/TH.
EXPERIMENTAL APPROACH: The model was established stepwise, starting with healthy adults, and extrapolated to paediatric (1 month-18 years) and neonatal (0-27 days, non-asphyxiated) populations. Finally, PA/TH-related physiological and metabolic changes were incorporated. For each population, performance was verified using clinical data.
KEY RESULTS: Model predictive performance for midazolam and 1'-hydroxymidazolam was acceptable in adults and children, with AFE and AAFE values ranging from 0.87 to 1.22 and 1.15 to 1.23, respectively. The neonatal PA/TH PBPK model captured midazolam pharmacokinetics, with 71% of the observations within the 10th-90th percentiles and 46% within the 25th-75th percentiles of the prediction. Incorporating PA/TH physiology improved the neonatal PA/TH model by 6%-43% (within the 10th-90th percentiles), depending on the compound.
CONCLUSIONS AND IMPLICATIONS: This PA/TH-adjusted neonatal PBPK model may support future midazolam dose optimization through mechanistic understanding and provides a framework for other drugs in neonates with PA/TH. Future knowledge on the impact of TH on protein binding and renal clearance of 1'-hydroxymidazolam-O-glucuronide would further improve the model.
EXPERIMENTAL APPROACH: The model was established stepwise, starting with healthy adults, and extrapolated to paediatric (1 month-18 years) and neonatal (0-27 days, non-asphyxiated) populations. Finally, PA/TH-related physiological and metabolic changes were incorporated. For each population, performance was verified using clinical data.
KEY RESULTS: Model predictive performance for midazolam and 1'-hydroxymidazolam was acceptable in adults and children, with AFE and AAFE values ranging from 0.87 to 1.22 and 1.15 to 1.23, respectively. The neonatal PA/TH PBPK model captured midazolam pharmacokinetics, with 71% of the observations within the 10th-90th percentiles and 46% within the 25th-75th percentiles of the prediction. Incorporating PA/TH physiology improved the neonatal PA/TH model by 6%-43% (within the 10th-90th percentiles), depending on the compound.
CONCLUSIONS AND IMPLICATIONS: This PA/TH-adjusted neonatal PBPK model may support future midazolam dose optimization through mechanistic understanding and provides a framework for other drugs in neonates with PA/TH. Future knowledge on the impact of TH on protein binding and renal clearance of 1'-hydroxymidazolam-O-glucuronide would further improve the model.